Background—Cardiac transplantation, a procedure nearly abandoned in the 1970s, has
evolved into the standard of care for appropriate patients with end-stage heart failure. Much
of this success has been due to improvements in immunosuppression, including the
introduction of a triple-drug regimen. Retrospective reports suggested that single-drug
immunosuppression with tacrolimus was feasible. As such, a prospective, randomized trial
was conducted to test this approach. Methods and Results—One hundred fifty adult de novo …